

Long-term Safety Trial with NVDX3

NCT06532253

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Novadip Biosciences
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (4)

- Patient being implanted with NVDX3.
- Previously participated to one of the NVDX3 core clinical trials.
- Patient accepts to comply to a yearly follow-up safety visit for 10 additional years
- Patient has understood and accepted to participate in the long-term follow-up study by signing the informed consent.

Locations (1 total)

Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg